LIXT (Lixte Biotechnology Holdings) חוב לטווח ארוך

Lixte Biotechnology (LIXT) relies on a lean staff of dedicated scientists and close ties with universities. The firm's environmental policy is based on the implementation of closed-loop water systems and the minimization of toxic waste. The market dynamics reflected in the price action captured the 0.00 metric. Business growth is driven by the success of the LB-100 drug in clinical trials and the development of partnerships with the world's leading oncology centers.

The specific nature of Lixte Biotechnology (LIXT) regarding patent protection for niche chemotherapeutic combinations requires significant capital, which is reflected in the issuer's long-term liabilities chart. This indicator aggregates all credit obligations with a maturity exceeding one year, allowing investors to assess the balance between investments in technological breakthroughs and financial stability risks should the cost of borrowed capital change.